TABLE 3.
Prognostic factors influencing the response of patients with segmental vitiligo (n=45)
| CATEGORY | N (%) | SUCCESS RATE, % (n) | MULTIVARIABLE ANALYSIS | UNIVARIABLE ANALYSIS | ||
|---|---|---|---|---|---|---|
| ODDS RATIO (95%% CI) | P-VALUE | ODDS RATIO (95% CI) | P-VALUE | |||
| Sex | ||||||
| Female | 32 (71.1) | 84.38 (27/32) | Reference | |||
| Male | ||||||
| Age of onset | ||||||
| >12 years | 24 (53.3) | 75 (18/24) | Reference | |||
| ≤12 years | 21 (46.7) | 80.95 (17/21) | 1.06 (0.17–6.89) | 0.95 | NA | |
| Disease duration | ||||||
| ≥12 years | 24 (53.3) | 62.5 (15/24) | Reference | Reference | ||
| 6–12 years | 4(8.9) | 100 (4/4) | 6.30 (0.45–86.49) | 0.17 | 2.44 (0.33–17.81) | 0.39 |
| ≤6 years | 17 (37.8) | 94.12 (16/17) | 0.92 (0.15–5.70) | 0.93 | 4.80 (1.36–16.78) | 0.01* |
| Site of vitiligo | ||||||
| Scalp | 1 (2.2) | 0(0/1) | Reference | Reference | ||
| Face | 21 (46.7) | 85.71 (18/21) | 298.87 (2.59–34891.55) | 0.95 | 188.67 (3.13–11271.13) | 0.01* |
| Waist | 7 (15.6) | 85.71 (6/7) | 237.46 (1.73–32869.62) | 0.03* | 105.64 (1.55–7269.01) | 0.03* |
| Leg | 2 (4.4) | 50 (1/2) | 5.31 (0.02–1107.65) | 0.54 | ||
| Hand | 1 (2.2) | 100 (1/1) | 9.49 (0.04–2724.39) | 0.44 | ||
| Neck | 6 (13.3) | 83.33 (5/6) | 162.38 (0.86–30946.03) | 0.06 | ||
| Scrotum | 1 (2.2) | 100 (1/1) | 90.92 (0.21–39735.49) | 0.15 | ||
| Chest, hand | 1 (2.2) | 100 (1/1) | 21.33 (0.06–7863.60) | 0.31 | ||
| Arm | 1 (2.2) | 0(0/1) | 10.07 (0.02–4675.07) | 0.46 | ||
| Groin | 2 (4.4) | 50 (1/2) | 0.11 (0.00–22.87) | 0.02* | ||
| Trunk | 1 (2.2) | 100 (1/1) | 204.38 (0.27–154817.14) | 0.12 | ||
| Back | 1 (2.2) | 100 (1/1) | 200.34 (0.24–167711.41) | 0.12 | ||
| Final dose | ||||||
| ≥900 MJ | 21 (46.7) | 66.67 (14/21) | Reference | Reference | ||
| 300–900 MJ | 24 (53.3) | 87.5 (21/24) | 15.96 (1.72–148.41) | 0.02* | 4.90 (1.49–16.28) | |
| Treatment sessions | ||||||
| ≥40 sessions | 20 (44.4) | 75 (15/20) | Reference | Reference | ||
| 20–40 sessions | 17 (37.8) | 76.47 (13/17) | 0.55 (0.07–4.10) | 0.56 | 1.84 (0.55–6.23) | 0.33 |
| ≤20 sessions | 8 (17.8) | 87.5(7/8) | 0.51 (0.02–11.82) | 0.67 | 8.50 (1.42–49.40) | 0.02* |
| Average energy | ||||||
| ≥400 MJ | 37 (82.2) | 75.68(28/37) | Reference | Reference | ||
| <400 MJ | 8 (17.8) | 87.5(7/8) | 5.00 (0.18–137.00) | 0.34 | 16.78 (2.05–137) | 0.01* |
*
statistically significant; p-value=0.05 considered to be significant
CI: confidence interval; NA: not applicable